European Parliament Poised To Ban Pfizer Representatives
Pfizer CEO Albert Bourla systematically refused to attend COVI committee meetings in October 2022 and December 2022, triggering protests from committee members.
Pfizer CEO Albert Bourla systematically refused to attend COVI committee meetings in October 2022 and December 2022, triggering protests from committee members.
The call for von der Leyen’s “immediate” and “unconditional” resignation comes as another MEP has urged the EU to “immediately terminate the contract on the procurement of vaccines against COVID-19” since the “contract is currently under criminal investigation by the EEPO.”
Croatian MEP Mislav Kolakušić said the EU Commission’s purchase of 4.5 billion vaccine doses for 450 million EU citizens is the biggest corruption scandal in human history.”
This admission will have “massive implications.” Governments from around the world had used guilt-shaming verbiage to get young people to take the vaccine.
It is not the first time that von der Leyen fell under an EU body’s scrutiny. In late January this year, the European Ombudsman launched an investigation to ascertain her role in negotiations with the U.S. pharmaceutical.
It has made some wonder if the Commission, particularly Von der Leyen, is not intentionally side-lining vaccines that could compete with Pfizer products.
European Ombudsman Emily O’Reilly called the incident “a wake-up call for all EU institutions about ensuring accountability in an era of instant messaging.”
In Poland, the vaccine campaign has not been as successful as expected. As a result, the government has a stock of 25 million unused vaccines, while an additional 67-70 million doses have been ordered.
Following increasing reports of quality control issues in batches of vaccines, as well as adverse effects, a group of chemistry professors expressed their concerns in an open letter to Germany’s control authority.
As long as the SMS messages between Ursula von den Leyen and Pfizer potentially concern EU policies and decisions, they should be treated as EU documents, and as such, made available to the public.
To submit a pitch for consideration:
submissions@
For subscription inquiries:
subscriptions@